Transplant Monitoring Demand And FDA Clearance Will Drive A Powerful Long Term Upswing

AnalystHighTarget

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published

14 Dec 25

Updated

08 Jul 26

Views

Not Invested

Shared on 08 Jul 26

Fair value Increased 33%

IMDX: Clinical Data And Registry Validation Will Support Higher Future Returns

New clinical results suggest Insight Molecular Diagnostics’ GraftAssure test closely matches a competing method and may help doctors make clearer transplant decisions, as the company starts a new registry to validate how it performs in real-world care. With more data set to be showcased at a major transplant meeting and work continuing toward FDA authorization for its kit, analysts are now more optimistic about the company’s future.

0 views

Fair Value vs Share Price

US$12

vs US$4.8559.6% undervalued

168%

Revenue growth

18.9%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Insight Molecular Diagnostics

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Slight risk with mediocre balance sheet.

Market capUS$154.7m

PB-14.6x

Estimated Growth67.1%

Dividend YieldN/A

Full analysis

CEO & management

Joshua Riggs

CEO

3.2yrs

CEO Tenure

Operates as a precision diagnostics company in the United States and internationally.